#USA #Chicago #Neurocrine Biosciences #CAHtalyst Study #CRF1 Antagonist

Promising Developments in Pediatric CAH Treatment

At the recent ENDO 2026 conference in Chicago, Neurocrine Biosciences, Inc. presented promising new data regarding the long-term use of CRENESSITY® (crinecerfont), a promising treatment for children suffering from classic congenital adrenal hyperplasia (CAH). This genetic condition affects the adrenal glands' hormone production, leading to excessive adrenal androgens and various complications, including abnormal growth patterns.

Neurocrine's Phase 3 CAHtalyst® Pediatric study revealed significant insights into how CRENESSITY can affect patients' growth metrics. The two-year data indicated that pediatric patients who had an accelerated bone age at baseline showed notable improvements in their growth patterns. Specifically, those on CRENESSITY experienced slowed progression of bone age and an increase in their predicted adult height. Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine, emphasized the importance of pediatric treatment decisions, which can have lifelong impacts on children with CAH. The data presented suggest that controlling adrenal androgens with CRENESSITY can potentially mitigate abnormal growth during critical developmental years.

Key Findings from the CAHtalyst Pediatric Study

In this study, 41 pediatric patients with CAH were assessed for changes in their bone age and predicted adult height after 24 months of treatment. Notably, 24 of these patients had advanced bone age at the start of the study. Remarkably, with continued treatment, the mean bone age standard deviation score (SDS) decreased by 1.12, with a subset of patients displaying reductions greater than two standard deviations. This improvement also correlated with an increase in predicted adult height averaging 4.7 cm, showcasing the potential of CRENESSITY to positively influence growth metrics.

Dr. Maria G. Vogiatzi, the principal investigator for the study, stated, "Accelerated bone age is one of the most challenging issues when managing CAH in children. The stabilization, and in some cases the improvement, of bone age over two years is encouraging. It signifies meaningful advancements in addressing a critical growth issue during developmental years."

Family Feedback: Optimism and Satisfaction

To complement their clinical findings, Neurocrine also conducted a caregiver survey among participants. The feedback was overwhelmingly positive. Each of the 29 participating caregivers expressed high satisfaction with CRENESSITY and noted improved optimism regarding their child’s long-term health outcomes. A significant proportion—79%—indicated reduced concerns regarding risks linked to high-dose steroid use, such as weight gain. Furthermore, 97% reported enhanced hope for their child's future while living with CAH.

Broader Implications for CAH Management

Data from the CAHtalyst Pediatric study builds upon earlier results showcasing how CRENESSITY facilitates substantial reductions in glucocorticoid doses, often linked to serious health complications when administered at supraphysiological levels. By effectively controlling androgen levels, CRENESSITY offers a safer and more effective therapeutic alternative for managing CAH, thereby potentially reducing cardiovascular risks for young patients.

Neurocrine’s commitment to refining treatment options for adolescents and children with CAH reflects a broader dedication to enhancing patient outcomes and reducing complications from traditional steroid therapies. With its recent findings, the company not only reaffirmed the efficacy of CRENESSITY but also showcased the profound difference it can make in the lives of young patients navigating the challenges of this complex endocrine disorder.

In summary, Neurocrine Biosciences' presentation at ENDO 2026 highlighted the encouraging data surrounding CRENESSITY's long-term treatment effects, significantly enhancing growth measures and improving caregiver perceptions of health outcomes. As the medical community continues to evolve in its understanding of CAH, innovations like CRENESSITY pave the way for improved patient care and quality of life for those affected by this condition.